Company news
KYORIN Pharmaceutical Co.,Ltd. news in 2026
KYORIN Pharmaceutical Co.,Ltd.'s news releases, calls and decks from 2026, newest first.
KYORIN and Acadia Pharmaceuticals Enter into Distribution Agreement for DAYBUE STIX (Trofinetide) for Rett Syndrome in Japan
November 16, 2026
[Summary]Consolidated Financial Results for the Six Months Ended September 30, 2026 [Japanese GAAP]
November 9, 2026
Notice Regarding Difference Between Financial Forecast and Actual Results and Revision
November 9, 2026
KYORIN and Edesa Biotech Enter into License Agreement for EB05 for ARDS (Acute Respiratory Distress Syndrome)
November 9, 2026
Consolidated Financial Results for Second Quarter of FY2026 - Supplementary Information
November 9, 2026
Notice Concerning Change in Major Shareholder
October 28, 2026
(Update on Disclosed Matter) Notice Regarding Transfer of Generic Drug Business
September 30, 2026
KYORIN to Commence Promotion Activities for Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5%
August 3, 2026
[Summary]Consolidated Financial Results for the Three Months Ended June 30, 2026 [Japanese GAAP]
July 30, 2026
KYORIN Entered into Joint Marketing Agreement in Japan for Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5%
July 13, 2026
KYORIN Pharmaceutical: Operating profit fell 71.6% year-over-year as sales declined and R&D costs rose
May 12, 2026
Kyorin Pharmaceutical Co Ltd - Kyorin Enters Into License Agreement With Biodol For Novel Neuropathic Pain Treatment
March 31, 2026
TABLE-Kyorin Pharmaceutical - 9-MTH group results
February 4, 2026
KYORIN Pharmaceutical: Strong nine-month results, but full-year outlook projects lower sales and profits
February 3, 2026
Decks in 2026
- Q2 FY2027 Earnings Presentation
Earnings · 24 slides · Nov 10, 2026
- FY2025 Earnings Presentation
Earnings · 24 slides · May 13, 2026